anti-emetics

DRUG2 trials

Sponsors

Pediatric Brain Tumor Consortium, National Cancer Institute (NCI)

Conditions

Hematologic MalignancyLeukemiaLymphomaMultiple MyelomaRecurrent EpendymomaRecurrent MedulloblastomaSolid Tumor Malignancy

Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active, not recruitingNCT04743661

Pediatric Brain Tumor ConsortiumRecurrent Ependymoma, Recurrent Medulloblastoma

Start: 2022-04-04End: 2027-09-30Target: 62Updated: 2026-02-05

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

CompletedNCT04847050

National Cancer Institute (NCI)Hematologic Malignancy, Leukemia, Lymphoma +2

Start: 2021-04-28End: 2023-05-25Updated: 2024-08-27